This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Fibrin sealant

Updated 2 Feb 2023 | Surgical sealants


Artiss sealant
Prefilled double chamber syringe which contains sealer protein solution in one chamber and thrombin solution in the other chamber.

Tisseel Lyo sealant
A two component fibrin sealant kit consisting of:

1 vial containing powder for sealer protein solution (human)

1 vial containing thrombin powder for solution

1 vial containing aprotinin solution solvent

1 vial containing calcium chloride solution

1 kit for reconstitution and application

Tisseel Ready to use sealant
Prefilled double chamber syringe which contains sealer protein solution in one chamber and thrombin solution in the other chamber.

Drugs List

  • ARTISS sealant
  • fibrin ready to use sealant
  • Therapeutic Indications


    Adjunct to haemostasis on subcutaneous tissue surfaces
    Improvement of haemostasis where surgical techniques insufficient
    Tissue glue in gastrointestinal anastomoses
    Tissue glue in neurosurgery where contact with CSF and dura matter possible
    Tissue glue in plastic, reconstructive and burn surgery


    The required dose of fibrin sealant depends on the clinical needs of the patient, the type of surgical intervention, the size of the surface to be covered, the application method chosen and the number of applications required.

    In clinical trials, individual doses have typically ranged from 0.2 to 20 ml depending on product used (see specific product literature). For some procedures, larger volumes have been used.

    The initial amount applied should be sufficient to entirely cover the intended application area. The application may be repeated if necessary.

    1 ml of fibrinogen solution plus 1 ml of thrombin solution will be sufficient to cover an area of at least 10 cm squared. If applied by spray application, the same quantity will be sufficient to coat considerably larger areas, depending on the specific indication and the individual case.

    To avoid the formation of excess granulation tissue and to ensure gradual absorption of the solidified fibrin sealant, only a thin layer of the fibrinogen-thrombin solution or the individual components should be applied. This also avoids possible pressure on the brain, spinal cord, cranial, and/or spinal nerves.

    Additional Dosage Information

    Apply fibrin sealant as a thin layer. Excessive clot thickness may negatively interfere with the product's efficacy and the wound healing process.


    For epilesional use.


    None known

    Precautions and Warnings

    Children under 18 years
    History of treatment with aprotinin

    Not all available brands are licensed for all indications
    Treatment to be initiated and supervised by a specialist
    Derived from human proteins - transmission of infective agents possible
    Cover all the tissue adjacent to the site of sealing before application
    Record name and batch number of administered product
    Remove solutions containing alcohol/iodine/heavy metals before application
    Resuscitation facilities must be immediately available
    Monitor blood pressure
    Anaphylactic reactions may occur following repeated administration
    Management of cases of shock should follow current medical standards
    Discontinue if hypersensitivity reactions occur

    Any application of pressurized gas is associated with a potential risk of air or gas embolism, tissue rupture or gas entrapment with compression, which may be life-threatening.

    Artiss sealant
    Once thawed, use within 14 days.

    Tisseel Lyo
    Use within 6 hours of reconstitution.

    Tisseel Ready to use
    Once thawed, use within 72 hours.

    Pregnancy and Lactation


    Use fibrin sealant with caution in pregnancy.

    The safety of fibrin sealants or haemostatics during human pregnancy has not been established.

    Animal studies are not sufficient to assess safety in terms of reproduction, embryo/foetal development, gestation or peri/post natal development

    No undesirable effects have been reported following the application of fibrin sealant during pregnancy.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Use fibrin sealant with caution in breastfeeding.

    The safety of fibrin sealants or haemostatics during breastfeeding has not been established.

    No undesirable effects have been reported following the application of fibrin sealant during lactation.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Allergic reaction
    Anaphylactic shock
    Anaphylactoid reaction
    Antibody formation
    Chest tightness
    Intravascular coagulation (disseminated)
    Irritation with burning (application site)
    Skin cysts
    Skin graft failure
    Tingling sensation


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: April 2015

    Reference Sources

    Summary of Product Characteristics: Artiss Solutions for Sealant. Baxter Healthcare Ltd. Revised April 2014.

    Summary of Product Characteristics: Tisseel Lyo Kit. Baxter Healthcare Ltd. Revised March 2013.

    Summary of Product Characteristics: Tisseel Ready to use. Baxter Healthcare Ltd. Revised March 2013.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.